Covid-19 roundup: Re­gen­eron asks FDA: Which gov­ern­ment agen­cies are track­ing vari­ants of con­cern?; Pfiz­er, As­traZeneca vac­cines most­ly hold strong against Delta vari­ant

As the race to keep Covid-19 vari­ants at bay con­tin­ues, Re­gen­eron is call­ing on the FDA to pro­vide ad­di­tion­al clar­i­ty on which gov­ern­ment agen­cies are ac­tu­al­ly track­ing and pub­lish­ing lists on vari­ants of con­cern like the Delta vari­ant.

The New York-based biotech, which has made a name for it­self dur­ing the pan­dem­ic for not on­ly treat­ing for­mer Pres­i­dent Trump with its an­ti­body cock­tail but al­so de­vel­op­ing a cock­tail that can with­stand the chang­ing na­ture of the coro­n­avirus in the US. Mean­while, its com­peti­tors from Eli Lil­ly were pulled from the mar­ket late last month as vari­ants were able to pen­e­trate the firm’s an­ti­body drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.